Wells Fargo Upgrades Edwards Lifesciences to Overweight, Announces $94 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen upgraded Edwards Lifesciences (NYSE:EW) from Equal-Weight to Overweight and set a $94 price target.
February 02, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo upgraded Edwards Lifesciences to Overweight from Equal-Weight and set a $94 price target.
Upgrades by major financial institutions like Wells Fargo generally lead to positive short-term price movements due to increased investor confidence and potential for reaching the set price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100